• Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7536457; PubMed=8275086).
  
• Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Heterozygous (DepMap=ACH-001740).
  
• Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058).
  

PubMed=3607778
Hazelton B.J., Houghton J.A., Parham D.M., Douglass E.C., Torrance P.M., Holt H., Houghton P.J.
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma.
Cancer Res. 47:4501-4507(1987)

CLPUB00569
Dickman P.S., Tsokos M.G., Triche T.J.
Biology of rhabdomyosarcoma: cell culture, xenografts, and animal models.
(In book chapter) Rhabdomyosarcoma and related tumors in children and adolescents; Maurer H.M., Ruymann F.B., Pochedly C.E. (eds.); pp.49-88; CRC Press; Boca Raton; USA (1991)

PubMed=8275086; DOI=10.1038/ng1193-230
Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Nat. Genet. 5:230-235(1993)

PubMed=8383879; DOI=10.1126/science.8383879
Tapscott S.J., Thayer M.J., Weintraub H.M.
Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.
Science 259:1450-1453(1993)

PubMed=7536457; DOI=10.1002/gcc.2870120305
Biegel J.A., Nycum L.M., Valentine V.A., Barr F.G., Shapiro D.N.
Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization.
Genes Chromosomes Cancer 12:186-192(1995)

PubMed=9802058
McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A., Harris L.C.
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
Oncol. Res. 10:235-244(1998)

PubMed=9823299
Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Cancer Res. 58:5009-5013(1998)

PubMed=11051265
Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.
Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
Clin. Cancer Res. 6:4119-4127(2000)

PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004; PMCID=PMC3241994
Belyea B.C., Naini S., Bentley R.C., Linardic C.M.
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Clin. Cancer Res. 17:7324-7336(2011)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056; PMCID=PMC3271129
Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)

PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=36768928; DOI=10.3390/ijms24032601; PMCID=PMC9917031
Timpanaro A., Piccand C., Uldry A.-C., Bode P.-K., Dzhumashev D., Sala R., Heller M., Rossler J., Bernasconi M.
Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma.
Int. J. Mol. Sci. 24:2601.1-2601.28(2023)